Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P57082
UPID:
TBX4_HUMAN
Alternative names:
-
Alternative UPACC:
P57082; A5PKU7; B2RMT1; B7ZLV3
Background:
T-box transcription factor TBX4 plays a pivotal role in the development of lungs, pelvis, and hindlimbs. It acts as a transcriptional regulator, essential for organogenesis. Mutations in TBX4 are linked to Ischiocoxopodopatellar syndrome, characterized by bone anomalies, and a syndrome involving absent hindlimbs and pelvic bones.
Therapeutic significance:
Understanding the role of T-box transcription factor TBX4 could open doors to potential therapeutic strategies for treating bone and organ development disorders. Its involvement in critical developmental pathways highlights its potential as a target for gene therapy.